Lipoxin A4 suppresses the development of endometriosis in an ALX receptor‐dependent manner via the p38 MAPK pathway
British Journal of Pharmacology2014Vol. 171(21), pp. 4927–4940
Citations Over TimeTop 10% of 2014 papers
Abstract
LXA4 exerted anti-inflammatory, anti-proliferative and anti-invasive effects on endometriosis through a mechanism that involved down-regulating the activities of p38 MAPK, which was mediated by ALX receptors.
Related Papers
- → Familial risk among Japanese patients with endometriosis(2003)47 cited
- → Biases in the endometriosis literature(1998)42 cited
- → Symptoms based endometriosis prediction using machine learning(2021)15 cited
- → Primate Model Research for Endometriosis(2012)33 cited
- → The Endometriosis - treatment and new methods(2023)